Currently, within the early-stage hormone receptor-positive patient population, treating physicians rely heavily on traditional clinicopathological criteria such as age, tumor size, and tumor grade to better quantify individual risk and direct systemic therapy. The gene discussed is NR4A1; the disease is neoplasm.